Oral Acid-Activated Hydrogen-Producing Nanoparticles Reduce Aortic Dissection Progression via RhoA/ROCK Inhibition in Mice
Source abstract
Abstract
Aortic dissection (AD) is a life-threatening condition with a high mortality rate. Oxidative stress and endothelial and vascular smooth muscle cell migration contribute to AD pathogenesis. Herein, we investigated the therapeutic potential of hydrogen (H 2 ), delivered via magnesium diboride nanosheets (MBNs), in a murine model of β-aminopropionitrile-induced AD. This treatment significantly improved survival rate and reduced AD progression, as evidenced by improved aortic wall structure and reduced false lumen formation. Transcriptomic analysis indicated modulation of the RhoA/ROCK pathway, confirmed using Western blotting, immunohistochemistry, and immunofluorescence, which showed significant downregulation of RhoA and ROCK2 after 28 days of treatment ( P < 0.05). These findings suggest that hydrogen released from MBNs attenuates AD progression through reactive oxygen species scavenging and RhoA/ROCK pathway inhibition.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Aortic Disease and Treatment Approaches · Advanced battery technologies research · Cardiac Ischemia and Reperfusion
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Cardiology
Affiliated Hospital of Shandong Second Medical University
Department of Nephrology
Department of Geriatrics
Department of Bioscience and Technology
Shandong Second Medical University
Funding
Weifang Medical University · National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Scientific research project of Weifang Health Committee · Weifang Science and Technology Development Plan · Weifang Youth Medical Talent Lifting Project · Medical and Health Technology of Shandong Province
References (63)
Show source-provided references
1. 10.1161/CIRCULATIONAHA.117.03126410.1161/CIRCULATIONAHA.117.031264 ↗
2. 10.1038/nrdp.2016.5310.1038/nrdp.2016.53 ↗
3. 10.1001/jama.2016.1002610.1001/jama.2016.10026 ↗
4. 10.1097/HCO.000000000000066710.1097/HCO.0000000000000667 ↗
5. 10.1161/CIRCULATIONAHA.113.00506210.1161/CIRCULATIONAHA.113.005062 ↗
6. 10.1016/j.cbi.2014.10.01610.1016/j.cbi.2014.10.016 ↗
7. 10.3389/fcvm.2021.67564710.3389/fcvm.2021.675647 ↗
8. 10.1007/s10557-020-07116-410.1007/s10557-020-07116-4 ↗
9. 10.1016/j.bcp.2019.03.03410.1016/j.bcp.2019.03.034 ↗
10. 10.1038/cr.2010.17810.1038/cr.2010.178 ↗
11. 10.1177/107424842091996610.1177/1074248420919966 ↗
12. 10.3390/ijms2005112210.3390/ijms20051122 ↗
13. 10.19540/j.cnki.cjcmm.20230320.60110.19540/j.cnki.cjcmm.20230320.601 ↗
14. 10.4103/0366-6999.22824910.4103/0366-6999.228249 ↗
15. 10.1007/s12031-019-01339-310.1007/s12031-019-01339-3 ↗
16. 10.3390/molecules2823778510.3390/molecules28237785 ↗
17. 10.31083/j.rcm250103310.31083/j.rcm2501033 ↗
18. 10.1007/s00204-023-03562-910.1007/s00204-023-03562-9 ↗
19. 10.33549/physiolres.93549110.33549/physiolres.935491 ↗
20. 10.3390/nu1109209010.3390/nu11092090 ↗
21. 10.3390/antiox912129210.3390/antiox9121292 ↗
22. 10.1038/s41598-020-68930-210.1038/s41598-020-68930-2 ↗
23. 10.1002/adhm.20190015710.1002/adhm.201900157 ↗
24. 10.1016/j.ijbiomac.2021.09.09910.1016/j.ijbiomac.2021.09.099 ↗
25. 10.1039/D1RA06556D10.1039/D1RA06556D ↗
26. 10.1007/978-1-4939-9009-2_2510.1007/978-1-4939-9009-2_25 ↗
27. 10.1002/adhm.20240040010.1002/adhm.202400400 ↗
28. 10.1016/j.vph.2020.10681010.1016/j.vph.2020.106810 ↗
29. 10.7150/ijbs.8020010.7150/ijbs.80200 ↗
30. 10.3390/ijms23211300910.3390/ijms232113009 ↗
31. 10.1016/j.intimp.2022.10908310.1016/j.intimp.2022.109083 ↗
32. 10.1016/j.vph.2023.10719210.1016/j.vph.2023.107192 ↗
33. 10.33549/physiolres.93534610.33549/physiolres.935346 ↗
34. 10.1126/scisignal.adk922410.1126/scisignal.adk9224 ↗
35. 10.1007/978-3-030-12457-1_2210.1007/978-3-030-12457-1_22 ↗
36. 10.1097/SLA.000000000000616410.1097/SLA.0000000000006164 ↗
37. 10.3390/ijms23191102510.3390/ijms231911025 ↗
38. 10.3390/ijms2122875010.3390/ijms21228750 ↗
39. 10.1161/HYPERTENSIONAHA.113.0150810.1161/HYPERTENSIONAHA.113.01508 ↗
40. 10.3390/antiox1202031510.3390/antiox12020315 ↗
41. 10.3390/molecules2621637510.3390/molecules26216375 ↗
42. 10.3390/cells1210136710.3390/cells12101367 ↗
43. 10.1186/s12890-023-02803-y10.1186/s12890-023-02803-y ↗
44. 10.1016/j.peptides.2006.08.03510.1016/j.peptides.2006.08.035 ↗
45. 10.3390/biom1102021210.3390/biom11020212 ↗
46. 10.1016/j.bbadis.2023.16681910.1016/j.bbadis.2023.166819 ↗
47. 10.1007/s11356-021-15337-910.1007/s11356-021-15337-9 ↗
48. 10.1016/j.neuint.2022.10527810.1016/j.neuint.2022.105278 ↗
49. 10.2174/1573403X1666620101414293010.2174/1573403X16666201014142930 ↗
50. 10.12968/hmed.2024.000410.12968/hmed.2024.0004 ↗
51. 10.1186/s12893-024-02499-910.1186/s12893-024-02499-9 ↗
52. 10.1053/j.semvascsurg.2024.04.00510.1053/j.semvascsurg.2024.04.005 ↗
53. 10.1016/j.vph.2024.10742010.1016/j.vph.2024.107420 ↗
54. 10.1042/CS2022079710.1042/CS20220797 ↗
55. 10.2174/138161282666620121111284610.2174/1381612826666201211112846 ↗
56. 10.21037/jtd-23-98110.21037/jtd-23-981 ↗
57. 10.1002/ieam.442610.1002/ieam.4426 ↗
58. 10.2174/092986732566618100814283110.2174/0929867325666181008142831 ↗
59. 10.1016/j.compbiomed.2024.10870210.1016/j.compbiomed.2024.108702 ↗
60. 10.1007/s11095-024-03798-910.1007/s11095-024-03798-9 ↗
61. 10.2174/138945012166620091609165910.2174/1389450121666200916091659 ↗
62. 10.3390/pharmaceutics1502061210.3390/pharmaceutics15020612 ↗
63. 10.1038/s41581-022-00585-w10.1038/s41581-022-00585-w ↗